^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    leuprolide acetate for depot suspension

    i
    Other names: TAP-144-SR, TAP-144SR, TAP-144, TAP-144-SR (6M), DWJ 108J, PT105
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    3d
    Study on the Improvement Effect of Probiotics on Perimenopausal Syndrome in Women with Infertility Induced by Leuprolide (ChiCTR2600117205)
    P=N/A, N=100, Not yet recruiting, Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine; Reproductive Hospital Affiliated to Jiangxi University of Trad
    New trial
    |
    leuprolide acetate for depot suspension
    7d
    c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=64, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Jan 2026 | Trial primary completion date: May 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • apalutamide • leuprolide acetate for depot suspension
    11d
    NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov)
    P2, N=32, Recruiting, Rana McKay, MD | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L2 (RAD54 Like 2)
    |
    Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    11d
    Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OncoPanel™ Assay
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    27d
    Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Chr t(15;17)
    |
    cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
    28d
    RWE About QOL and Compliance of Patients With OFS in China (clinicaltrials.gov)
    P=N/A, N=562, Completed, Fudan University | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Nov 2024 --> May 2025
    Trial completion date • Trial primary completion date • Real-world evidence • Compliance
    |
    goserelin acetate • leuprolide acetate for depot suspension
    1m
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | N=220 --> 532
    Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    1m
    Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    sunitinib • leuprolide acetate for depot suspension
    2ms
    The Role of Hormones in Postpartum Mood Disorders (clinicaltrials.gov)
    P2, N=74, Completed, National Institute of Mental Health (NIMH) | N=54 --> 74
    Enrollment change
    |
    leuprolide acetate for depot suspension
    2ms
    Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature. (PubMed, Case Rep Oncol)
    We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy...As second-line therapy, he received gemcitabine and docetaxel...Alternative regimens include temozolomide plus irinotecan or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.
    Journal
    |
    AR (Androgen receptor) • WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1)
    |
    AR positive
    |
    gemcitabine • docetaxel • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • bicalutamide • leuprolide acetate for depot suspension
    2ms
    Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Nov 2028 | Trial primary completion date: Jan 2027 --> Nov 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • Nubeqa (darolutamide) • apalutamide • triptorelin • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2ms
    POP-ELA: A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=140, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER positive
    |
    Orserdu (elacestrant) • leuprolide acetate for depot suspension